References

• Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: Presentation, nosology, and epidemiology. J Child Psychol Psychiatry 2006; 47 (3–4): 313–37.
   PubMed Web of Science ®Google Scholar
• Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46(12): 1532–72.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Jensen PS, Abikoff H, Blumer JL, Deveaugh-Geiss J, Fisher C, et al. Developing strategies for psychopharmacological studies in preschool children. J Am Acad Child Adolesc Psychiatry 2003; 42(4): 406–14.
   Web of Science ®Google Scholar
• Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45(11): 1294–303.
   PubMed Web of Science ®Google Scholar
• Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol 2008; 18(5): 413–47.
   PubMed Web of Science ®Google Scholar
• Riddle MA. New Findings from the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) J Child Adolesc Psychopharmacol 2007; 17(5): 543–6.
   Web of Science ®Google Scholar
• Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16(5): 575–87.
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003; 64(9): 1039–47.
   PubMed Web of Science ®Google Scholar
• Coskun M, Zoroglu S, Ozturk M. Risperidone treatment in preschool children with disruptive behavior disorders: A chart review study. Klinik Psikofarmakoloji Bülteni-Bulletin Clinical Psychopharmacology 2011; 21(1): 33–41. (Turkish)
   Web of Science ®Google Scholar
• Coskun M, Zoroglu S. Efficacy and Safety of Fluoxetine in Preschool Children with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol 2009; 19(3): 297–300.
   Web of Science ®Google Scholar
• Oner O, Oner P. Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports. J Psychopharmacol 2008; 22(7): 809–11.
   Web of Science ®Google Scholar
• Avci A, Diler RS, Tamam L. Fluoxetine treatment in a 2.5-year-old girl. J Am Acad Child Adolesc Psychiatry 1988; 37(9): 901–2.
   Google Scholar
• Zuckerman ML, Vaughan BL, Whitney J, Dodds A, Yakhkind A, MacMillan C, et al. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: A retrospective chart review. J Child Adolesc Psychopharmacol 2007; 17(2): 165–74.
   Web of Science ®Google Scholar
• Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, et al. Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41(12): 1431–38.
   PubMed Web of Science ®Google Scholar
• Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42(4): 415–23.
   PubMed Web of Science ®Google Scholar
• The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344(17): 1279–85.
   Web of Science ®Google Scholar
• Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61(11): 1153–62.
   PubMed Web of Science ®Google Scholar
• Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158(12): 2008–14.
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein DJ, Ziervogel C, Middleton T, Kaminer D, Emsley RA, et al. Comparison of response to selective serotonin reuptake inhibitor in children, adolescents, and adults with PTSD. J Child Adolesc Psychopharmacol 2002; 12(1): 37–46.
   PubMed Web of Science ®Google Scholar
• Yorbik O, Dikkatli S, Cansever A, Sohmen T. The efficacy of fluoxetine treatment in children and adolescents with posttraumatic stress disorder symptoms (Turkish). Klinik Psikofarmakoloji Bülteni- Bulletin of Clinical Psychopharmacology 2001; 11(4): 251–6.
   Google Scholar
• Cohen JA, Mannarino AP, Perel JM, Staron V. A pilot randomized trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry 2007; 46(7): 811–9.
   Web of Science ®Google Scholar
• Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, et al. Paroxetine treatment in children and adolescents with obsessivecompulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43(11): 1387–96.
   PubMed Web of Science ®Google Scholar
• Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 2007; 17(6): 751–60.
   Web of Science ®Google Scholar
• Ahn JH, Patkar AA. Escitalopram for the treatment of major depressive disorder in youth. Expert Opin Pharmacother 2011; 12(14): 2235–44.
   Web of Science ®Google Scholar
• Gualtieri CT, Johnson LG. Antidepressant Side Effects in Children and Adolescents. J Child Adolesc Psychopharmacol 2006; 16 (1–2): 147–57.
   PubMed Web of Science ®Google Scholar
• Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents. J Child Adolesc Psychopharmacol 2006; 16(1–2): 159–69.
   PubMed Web of Science ®Google Scholar
• Walkup J, Labellarte M. Complications of SSRI Treatment. J Child Adolesc Psychopharmacol 2001; 11(1): 1–4.
   PubMed Web of Science ®Google Scholar